desogestrel + ethinylestradiol




Zuellig Pharma


A. Menarini
Concise Prescribing Info
Desogestrel 150 mcg, ethinylestradiol 20 mcg
Dosage/Direction for Use
1 tab daily starting on 1st day of menstruation w/o interruption for 21 days, then 7 tab-free days.
May be taken with or without food: Take at the same time each day.
Hypersensitivity. Presence or history of venous, arterial thrombosis or prodromal conditions (eg, transient ischaemic attack, angina pectoris). Known predisposition & presence of severe or multiple risk factors for venous or arterial thrombosis. History of migraine w/ focal neurological symptoms; DM w/ vascular involvement; pancreatitis or history associated w/ severe hypertriglyceridaemia; known or suspected sex steroid-influenced malignancies; undiagnosed vag bleeding; severe HTN; endometrial hyperplasia; porphyria; hyperlipoproteinaemia. Major surgery w/ prolonged immobilization. Severe pruritus or herpes gestationis. Concomitant use w/ HCV combination drug. Severe hepatic disease; cholestatic jaundice; Rotor & Dubin-Johnson syndrome; benign or malignant liver tumours. Known or suspected pregnancy.
Special Precautions
Increased risk of venous or arterial thrombosis & thromboembolic diseases; increasing age, +ve family history of venous or arterial thromboembolism, obesity, prolonged immobilisation, major surgery & trauma, leg surgery, superficial thrombophlebitis, varicose veins, smoking, dyslipoproteinaemia, HTN, migraine, valvular heart disease, atrial fibrillation; DM; SLE; haemolytic uraemic syndrome, Crohn's disease or ulcerative colitis; sickle cell disease. Hypertriglyceridaemia; gallstone formation; porphyria; Sydenham's chorea; herpes gestationis; otosclerosis-related hearing loss; hereditary angioedema. Chloasma; depression; GI disturbances. Monitor patients w/ latent or overt cardiac failure, epilepsy, sickle cell haemoglobinopathy, estrogen-sensitive gynaecological disorders. HCV combination drug regimen. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Exclude malignancy prior to therapy; irregular bleeding (eg, spotting or breakthrough bleeding) during 1st mth of use. Benign & malignant liver tumours; jaundice &/or pruritus related to cholestasis. Renal dysfunction. Not to be used during pregnancy. Not recommended during lactation.
Adverse Reactions
Depression, altered mood; headache; nausea, abdominal pain; breast pain & tenderness; increased wt.
Drug Interactions
Increased clearance, reduced plasma conc & decreased efficacy w/ phenytoin, phenobarb, primidone, bosentan, carbamazepine, rifampicin, oxcarbazepine, topiramate, felbamate, griseofulvin, HIV PIs, NNRTIs, St. John's wort. Increased or decreased plasma conc w/ nelfinavir, nevirapine, boceprevir, telaprevir. Increased serum conc w/ strong (eg, ketoconazole, itraconazole, clarithromycin) or moderate (eg, fluconazole, diltiazem, erythromycin) CYP3A4 inhibitors. Increased plasma & tissue conc of ciclosporin. Decreased plasma & tissue conc of lamotrigine.
MIMS Class
Oral Contraceptives
ATC Classification
G03AA09 - desogestrel and ethinylestradiol ; Belongs to the class of progestogens and estrogens in fixed combinations. Used as systemic contraceptives.
Mercilon tab
3 × 21's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in